Subscribe for email alerts
Donate to Science & Enterprise
|
By Alan, on June 7th, 2023%
A developer of nanoscale lipid particles for delivering genomic therapies to specific cells and tissue, spun-off from academic labs, is raising $25 million in seed funds. . . . → Read More: Targeted Genetic Nanoparticle Company Gains $25M in Seed Funds
By Alan, on June 6th, 2023%
Initial results from a clinical trial show a patch device delivering a Covid-19 vaccine is well tolerated by recipients and triggers a measurable immune response. . . . → Read More: Vaccine Patch Shown Safe, Induces Immune Response
By Alan, on June 1st, 2023%
A clinical trial is underway testing an experimental therapy for peanut allergy that its developer says trains the immune system without using peanut proteins. . . . → Read More: Clinical Trial Begins for Peanut Allergy Treatment
By Alan, on May 31st, 2023%
A clinical trial shows an oral therapy with engineered viruses delivers precise gene-edited payloads to reduce E. coli communities in the gut with no serious adverse effects. . . . → Read More: Crispr Therapy Shown to Reduce Harmful Gut Microbes
By Alan, on May 30th, 2023%
A clinical trial has begun testing a treatment for solid tumor cancers using engineered T-cells with proteins to attack specific tumor cells, but also avoid healthy cells. . . . → Read More: Precision T-Cell Solid Tumor Therapy Trial Underway
By Alan, on May 27th, 2023%
A recent poll shows U.S. adults continue to favor vaccinations against the childhood diseases mumps, measles, and rubella, but show less support for Covid-19 vaccines. . . . → Read More: Infographic – More US Support for Childhood Vaccines Than Covid-19
By Alan, on May 26th, 2023%
Results of a small clinical trial show most patients with melanoma receiving a personalized therapeutic vaccine with an approved immunotherapy reduced at least some of their tumors. . . . → Read More: AI-Designed Cancer Vaccine Shown to Act Against Melanoma
By Alan, on May 25th, 2023%
Interim results from a clinical trial show a drug given as a dissolvable oral film in a lower dose reduces agitation in people with bipolar disorder and schizophrenia. . . . → Read More: Low-Dose Oral Film Reduces Mental Disorder Agitation
By Alan, on May 24th, 2023%
A global drug maker is acquiring access to a biotechnology company’s precise genome editing techniques to develop new therapies for rare and cardiometabolic disorders. . . . → Read More: Pharma Company Gains Precise Gene Edits in $2B Biotech Deal
By Alan, on May 22nd, 2023%
A biotechnology company says it identified engineered precursors of a psychedelic compound that in lab animals produce safe and intended therapeutic effects. . . . → Read More: Safer Forms of Psilocybin Assessed in Preclinical Study
|
Welcome to Science & Enterprise Science and Enterprise is an online news service begun in 2010, created for researchers and business people interested in taking scientific knowledge to the marketplace.
On the site’s posts published six days a week, you find research discoveries destined to become new products and services, as well as news about finance, intellectual property, regulations, and employment.
|